# Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients

> **NCT01149109** · PHASE3 · COMPLETED · sponsor: **University Hospital, Bonn** · enrollment: 141 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Temozolomide and lomustine
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT01149109
- **Lead sponsor:** University Hospital, Bonn
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2017-04-06
- **Final completion:** 2017-04-06
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01149109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01149109, "Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01149109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*